Surmodics

SRDX

ATLANTA, GA – – (Newsfile Corp. – January 23, 2023) – – Holzer & Holzer, LLC is investigating whether Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX) complied with federal securities laws.  On January 19, 2023, the Company issued a press release regarding its premarket approval application (PMA) for SurVeil ™ stating: “the FDA indicated that the application is not currently approvable” and that “certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company’s PMA application to place it in approvable form.” Following that news, the Company’s stock dropped again.

If you purchased Surmodics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/surmodics/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.